Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

A phase I trial of ABT-888 (veliparib), a poly(ADP-ribose) polymerase (PARP inhibitor), in combination with topotecan, a topoisomerase I–targeted agent, was performed to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refract...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kummar, Shivaani, Chen, Alice, Ji, Jiuping, Zhang, Yiping, Reid, Joel M., Ames, Matthew, Jia, Lee, Weil, Marcie, Speranza, Giovanna, Murgo, Anthony J., Kinders, Robert, Wang, Lihua, Parchment, Ralph E., Carter, John, Stotler, Howard, Rubinstein, Larry, Hollingshead, Melinda, Melillo, Giovanni, Pommier, Yves, Bonner, William, Tomaszewski, Joseph E., Doroshow, James H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166628/
https://ncbi.nlm.nih.gov/pubmed/21795476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-1227
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares